# EDGAR Filing Document

**Accession Number:** 0001831363
**File Stem:** 0001193125-26-132108
**Filing Date:** 2026-3
**Character Count:** 23497
**Document Hash:** 6e3d03f9a94da1cb6e3a945d369e16a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-132108.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001193125-26-132108

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260330

**EFFECTIVENESS DATE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Terns Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001831363
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294733
- **FILM NUMBER:** 26814274

**BUSINESS ADDRESS:**
- **STREET 1:** 1065 EAST HILLSDALE BLVD., SUITE 100
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 650-525-5535 EXT.101

**MAIL ADDRESS:**
- **STREET 1:** 1065 EAST HILLSDALE BLVD., SUITE 100
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**As filed with the Securities and Exchange Commission on March 30, 2026**

**Registration No. 333-**

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER THE SECURITIES ACT OF 1933***

------

**Terns Pharmaceuticals, Inc.**

**(Exact name of Registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **98-1448275** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(I.R.S. Employer<br>Identification Number)** |
| **1065 East Hillsdale Blvd., Suite 100<br>Foster City, California** | <br>**94404** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

------

**2021 Incentive Award Plan**

**2022 Employment Inducement Award Plan, as amended**

**2021 Employee Stock Purchase Plan** 

**(Full Title of the Plan)**

------

**Amy Burroughs, M.B.A.**

**Chief Executive Officer**

**Terns Pharmaceuticals, Inc.**

**1065 East Hillsdale Blvd., Suite 100**

**Foster City, California 94404**

**(650) 525-5535**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

------

---

| | |
|:---|:---|
| &nbsp;&nbsp; <br>**Brian A. Johnson**<br>**Wilmer Cutler Pickering Hale and Dorr LLP**<br>**7 World Trade Center**<br>**250 Greenwich Street**<br>**New York, New York 10007**<br>**Telephone: (212) 230-8800**<br>| &nbsp;&nbsp;***Copies to:***<br>**Caryn McDowell, Esq.**<br>**Chief Legal Officer**<br>**Terns Pharmaceuticals, Inc.**<br>**1065 East Hillsdale Blvd., Suite 100**<br>**Foster City, California 94404**<br>**(650) 525-5535** |

---

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;Large accelerated filer | &nbsp;&nbsp;☐ | &nbsp;&nbsp;Accelerated filer | &nbsp;&nbsp;☐ |
| &nbsp;&nbsp;Non-accelerated filer | &nbsp;&nbsp;☒ | &nbsp;&nbsp;Smaller reporting company | &nbsp;&nbsp;☒ |
|  |  | &nbsp;&nbsp;Emerging growth company | &nbsp;&nbsp;☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Proposed sale to take place as soon after the effective date of the<br>registration statement as awards under the plans are exercised and/or vest.**

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 8,369,288 shares of the Registrant's common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Forms S-8 (File Nos. 333-253085, 333-263340, 333-268277, 333-271944, 333-275549, 333-277943, 333-283169 and 333-285966) are effective: (i) the 2021 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 5,616,234 shares of common stock; (ii) the 2022 Employment Inducement Award Plan, as amended, which added 2,000,000 shares of common stock pursuant to Amendment No. 3 to the 2022 Employment Inducement Award Plan, approved by the Board of Directors of the Company and effective as of January 1, 2026; and (iii) the 2021 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 753,054 shares of common stock.

**INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON<br>FORM S-8**

Pursuant to General Instruction E of Form S-8, the contents of the Registrant's Registration Statements on Forms S-8 (File Nos. [<u>333-253085</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521041825/d137290ds8.htm), [<u>333-263340</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312522067930/d295777ds8.htm), [<u>333-268277</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017022023992/tern-s8-q322.htm), [<u>333-271944</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017023022257/tern-s8-q123.htm), [<u>333-275549</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017023063755/tern-s8-q323.htm), [<u>333-277943</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017024031601/tern-s8-q124.htm), [<u>333-283169</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017024125651/tern-s8-q324.htm) and [<u>333-285966</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017025042727/tern-s8-q125.htm)), filed with the Commission on February 12, 2021, March 7, 2022, November 9, 2022, May 15, 2023, November 14, 2023, March 14, 2024, November 12, 2024 and March 20, 2025, respectively, are hereby incorporated by reference.

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

**Item 8. Exhibits**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** |  |
| &nbsp;&nbsp;**Exhibit Number** | &nbsp;&nbsp;**Exhibit Description** | &nbsp;&nbsp;**Form** | &nbsp;&nbsp;**Date** | &nbsp;&nbsp;**Number** | &nbsp;&nbsp;**Filed Herewith** |
| &nbsp;&nbsp;4.1 | &nbsp;&nbsp;[<u>Amended and Restated Certificate of Incorporation.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521034352/d115818dex31.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;2/9/2021 | &nbsp;&nbsp;3.1 |  |
| &nbsp;&nbsp;4.2 | &nbsp;&nbsp;[<u>Amended and Restated Bylaws.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017023052653/tern-ex3_1.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;10/10/2023 | &nbsp;&nbsp;3.1 |  |
| &nbsp;&nbsp;4.3 | &nbsp;&nbsp;[<u>Form of Common Stock Certificate.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521023654/d56372dex42.htm) | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;2/1/2021 | &nbsp;&nbsp;4.2 |  |
| &nbsp;&nbsp;5.1 | &nbsp;&nbsp;[<u>Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.</u>](tern-ex5_1.htm) |  |  |  | &nbsp;&nbsp;X |
| &nbsp;&nbsp;23.1 | &nbsp;&nbsp;[<u>Consent of Independent Registered Public Accounting Firm.</u>](tern-ex23_1.htm) |  |  |  | &nbsp;&nbsp;X |
| &nbsp;&nbsp;23.2 | &nbsp;&nbsp;[<u>Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).</u>](tern-ex5_1.htm) |  |  |  | &nbsp;&nbsp;X |
| &nbsp;&nbsp;24.1 | &nbsp;&nbsp;[<u>Power of Attorney. Reference is made to the signature page to the Registration Statement.</u>](#power_of_attorney) |  |  |  | &nbsp;&nbsp;X |
| &nbsp;&nbsp;99.1(a)# | &nbsp;&nbsp;[<u>2021 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521041825/d137290dex992a.htm) | &nbsp;&nbsp;S-8 | &nbsp;&nbsp;2/12/2021 | &nbsp;&nbsp;99.2(a) |  |
| &nbsp;&nbsp;99.1(b)# | &nbsp;&nbsp;[<u>Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521023654/d56372dex105b.htm) | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;2/1/2021 | &nbsp;&nbsp;10.5(b) |  |
| &nbsp;&nbsp;99.1(c)# | &nbsp;&nbsp;[<u>Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521023654/d56372dex105c.htm) | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;2/1/2021 | &nbsp;&nbsp;10.5(c) |  |
| &nbsp;&nbsp;99.1(d)# | &nbsp;&nbsp;[<u>Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521023654/d56372dex105d.htm). | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;2/1/2021 | &nbsp;&nbsp;10.5(d) |  |
| &nbsp;&nbsp;99.2# | &nbsp;&nbsp;[<u>2021 Employee Stock Purchase Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000119312521041825/d137290dex993.htm) | &nbsp;&nbsp;S-8 | &nbsp;&nbsp;2/12/2021 | &nbsp;&nbsp;99.3 |  |
| &nbsp;&nbsp;99.3(a)# | &nbsp;&nbsp;[<u>2022 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017022023982/tern-ex10_1a.htm) | &nbsp;&nbsp;10-Q | &nbsp;&nbsp;11/9/2022 | &nbsp;&nbsp;10.1(a)# |  |
| &nbsp;&nbsp;99.3(b)# | &nbsp;&nbsp;[<u>Amendment No. 1 to 2022 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017023063380/tern-ex10_2.htm) | &nbsp;&nbsp; 10-Q | &nbsp;&nbsp;11/14/2023 | &nbsp;&nbsp;10.2# |  |
| &nbsp;&nbsp;99.3(c)# | &nbsp;&nbsp;[<u>Amendment No. 2 to 2022 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017024125584/tern-ex10_3.htm) | &nbsp;&nbsp; 10-Q | &nbsp;&nbsp;11/12/2024 | &nbsp;&nbsp;10.3# |  |
| &nbsp;&nbsp;99.3(d)# | &nbsp;&nbsp;[<u>Amendment No. 3 to 2022 Employment Inducement Award Plan.</u>](tern-ex99_3d.htm) |  |  |  | &nbsp;&nbsp;X |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** | &nbsp;&nbsp;**Incorporated by Reference** |  |
| &nbsp;&nbsp;**Exhibit Number** | &nbsp;&nbsp;**Exhibit Description** | &nbsp;&nbsp;**Form** | &nbsp;&nbsp;**Date** | &nbsp;&nbsp;**Number** | &nbsp;&nbsp;**Filed Herewith** |
| &nbsp;&nbsp;99.4(a)# | &nbsp;&nbsp;[<u>Form of Stock Option Grant Notice and Stock Option Agreement under the 2022 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017022023982/tern-ex10_1b.htm) | &nbsp;&nbsp;10-Q<br>| &nbsp;&nbsp;11/9/2022<br>| &nbsp;&nbsp;10.1(b)#<br>|  |
| &nbsp;&nbsp;99.4(b)# | &nbsp;&nbsp;[<u>Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Employment Inducement Award Plan.</u>](https://www.sec.gov/Archives/edgar/data/1831363/000095017022023982/tern-ex10_1c.htm) | &nbsp;&nbsp;10-Q<br>| &nbsp;&nbsp;11/9/2022<br>| &nbsp;&nbsp;10.1(c)#<br>|  |
| &nbsp;&nbsp;107 | &nbsp;&nbsp;[<u>Calculation of Filing Fee Tables</u>](tern_exfilingfees.htm) |  |  |  | &nbsp;&nbsp;X |

---

# Indicates management contract or compensatory plan.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on this 30<sup>th</sup> day of March, 2026.

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Terns Pharmaceuticals, Inc.** | &nbsp;&nbsp;**Terns Pharmaceuticals, Inc.** |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Amy Burroughs |
|  | &nbsp;&nbsp;Amy Burroughs, M.B.A. |
|  | &nbsp;&nbsp;*Chief Executive Officer* |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Amy Burroughs and Andrew Gengos, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Signature** | &nbsp;&nbsp;**Title** | &nbsp;&nbsp;**Date** |
| &nbsp;&nbsp;/s/ Amy Burroughs | &nbsp;&nbsp;Chief Executive Officer and Director<br>*(Principal Executive Officer)* | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Amy Burroughs, M.B.A.<br>| &nbsp;&nbsp;Chief Executive Officer and Director<br>*(Principal Executive Officer)* |  |
| &nbsp;&nbsp;/s/ Andrew Gengos | &nbsp;&nbsp;Chief Financial Officer<br>*(Principal Financial and Accounting Officer)* | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Andrew Gengos, M.B.A. | &nbsp;&nbsp;Chief Financial Officer<br>*(Principal Financial and Accounting Officer)* |  |
| &nbsp;&nbsp;/s/ David Fellows | &nbsp;&nbsp;Chairman of the Board of Directors | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;David Fellows |  |  |
| &nbsp;&nbsp;/s/ Robert Azelby | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Robert Azelby |  |  |
| &nbsp;&nbsp;/s/ Jeffrey Kindler | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Jeffrey Kindler, Esq. |  |  |
| &nbsp;&nbsp;/s/ Jill Quigley | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Jill Quigley, Esq. |  |  |
| &nbsp;&nbsp;/s/ Radhika Tripuraneni | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Radhika Tripuraneni, M.D. |  |  |
| &nbsp;&nbsp;/s/ Heather Turner | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 30, 2026 |
| &nbsp;&nbsp;Heather Turner, Esq. |  |  |

---

------

## Exhibit 5.1

**Exhibit 5.1**

![img60210087_0.gif](img60210087_0.gif)

+1 212 230-8800 (t)+1 212 230 8888 (f)

@wilmerhale.com

March 30, 2026

Terns Pharmaceuticals, Inc.

1065 East Hillsdale Blvd., Suite 100

Foster City, California 94404

Re: 2021 Incentive Award Plan

2022 Employment Inducement Award Plan, as amended<br>2021 Employee Stock Purchase Plan

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 8,369,288 shares of common stock, $0.0001 par value per share (the "Shares"), of Terns Pharmaceuticals, Inc., a Delaware corporation (the "Company"), issuable under the Company's 2021 Incentive Award Plan, 2022 Employment Inducement Award Plan, as amended, and 2021 Employee Stock Purchase Plan (collectively, the "Plans").

We have examined the Certificate of Incorporation and Bylaws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings and actions of the board of directors and stockholders of the Company, the Registration Statement, the Plans and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

![img60210087_1.jpg](img60210087_1.jpg)

------

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plans, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

<u>/s/ Wilmer Cutler Pickering Hale and Dorr LLP</u>

WILMER CUTLER PICKERING <br> HALE AND DORR LLP

------

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2021 Incentive Award Plan, the 2021 Employee Stock Purchase Plan, and the 2022 Employment Inducement Award Plan (as amended), of Terns Pharmaceuticals, Inc. of our report dated March 30, 2026, with respect to the consolidated financial statements of Terns Pharmaceuticals, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California

March 30, 2026

------

## Exhibit 99.3

**Exhibit 99.3(d)**

**AMENDMENT NO. 3 TO**

**2022 EMPLOYMENT INDUCEMENT AWARD PLAN OF**

**TERNS PHARMACEUTICALS, INC.**

The 2022 Employment Inducement Award Plan, as amended (the "Plan") of Terns Pharmaceuticals, Inc. (the "Company") is hereby further amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Section 5.1 of the Plan be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Number of Shares</u>. Subject to adjustment under Article IX and the terms of this Article V, Awards may be made under the Plan covering up to 8,763,250 Shares. Shares issued or delivered under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Except as set forth herein, the Plan shall remain in full force and effect.

\* \* \*

*Approved by the Compensation Committee of the Board of Directors effective as of January 1, 2026.*

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Calculation of** Filing Fee Tables

---

| |
|:---|
| &nbsp;&nbsp;**Form** S-8 |
| &nbsp;&nbsp;(Form Type) |
| &nbsp;&nbsp;Terns Pharmaceuticals, Inc. |
| &nbsp;&nbsp;(Exact Name of Registrant as Specified in its Charter) |

---

**Table 1—Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security<br>Type** | **Security Class <br>Title** | **Fee <br>Calculation<br>Rule** | **Amount <br>Registered <br>(1)** | **Proposed <br>Maximum <br>Offering<br>Price Per<br>Share (2)** | **Maximum <br>Aggregate <br>Offering Price** | **Fee Rate** | **Amount of <br>Registration <br>Fee** |
| &nbsp;&nbsp;Equity | Common Stock, $0.0001 par value per share | &nbsp;&nbsp;457(c) and 457(h) | &nbsp;&nbsp;8,369,288 shares (3) | $49.26 | $412271126.88 | &nbsp;&nbsp;$0.00013810 | $56934.65 |
| &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;**Total Offering Amounts** |  | $412271126.88 |  | $56934.65 |
| &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** | &nbsp;&nbsp;**Total Fee Offsets** |  |  |  |  |
| &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;**Net Fee Due** |  |  |  | $56934.65 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock that becomes issuable under the 2021 Incentive Award Plan (the "2021 Plan"), the 2022 Employment Inducement Award Plan, as amended (the "2022 Plan") and the 2021 Employee Stock Purchase Plan ("ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant's outstanding shares of common stock.

(2) Pursuant to 457(c) and 457(h) under the Securities Act, the proposed maximum offering price per share is estimated solely for the purpose of calculating the registration fee and is based upon the average of the high and low prices of the Registrant's common stock as reported on the Nasdaq Global Select Market on March 24, 2026, which date is within five business days prior to filing this Registration Statement.

(3) Consists of (i) 5,616,234 additional shares of the Registrant's common stock that became available for issuance on January 1, 2026 under the 2021 Plan, by operation of an automatic annual increase provision therein; (ii) 2,000,000 additional shares of the Registrant's common stock under the 2022 Plan that became available for issuance on January 1, 2026, pursuant to Amendment No. 3 to the 2022 Plan approved by the Board of Directors of the Registrant; and (iii) 753,054 additional shares of the Registrant's common stock that became available for issuance on January 1, 2026 under the ESPP, by operation of an automatic annual increase provision therein.

------